BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34927371)

  • 1. Development and validation of a prediction model using molecular marker for long-term survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy.
    Yang Y; Zhang T; Zhou Z; Liang J; Chen D; Feng Q; Xiao Z; Hui Z; Lv J; Deng L; Wang X; Wang W; Wang J; Liu W; Zhai Y; Wang J; Bi N; Wang L
    Thorac Cancer; 2022 Feb; 13(3):296-307. PubMed ID: 34927371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development and external validation of an overall survival nomogram in medically inoperable centrally located early-stage non-small cell lung carcinoma.
    Duijm M; Oomen-de Hoop E; van Voort van der Zyp N; van de Vaart P; Tekatli H; Hoogeman M; Senan S; Nuyttens J
    Radiother Oncol; 2021 Mar; 156():223-230. PubMed ID: 33418006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival Nomogram for Stage IB Non-Small-Cell Lung Cancer Patients, Based on the SEER Database and an External Validation Cohort.
    Zuo Z; Zhang G; Song P; Yang J; Li S; Zhong Z; Tan Q; Wang L; Xue Q; Gao S; Sun N; He J
    Ann Surg Oncol; 2021 Jul; 28(7):3941-3950. PubMed ID: 33249521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma.
    Zhang LL; Xu F; Song D; Huang MY; Huang YS; Deng QL; Li YY; Shao JY
    JAMA Netw Open; 2020 Dec; 3(12):e2029882. PubMed ID: 33306119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer.
    Liang W; Zhang L; Jiang G; Wang Q; Liu L; Liu D; Wang Z; Zhu Z; Deng Q; Xiong X; Shao W; Shi X; He J
    J Clin Oncol; 2015 Mar; 33(8):861-9. PubMed ID: 25624438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
    Kang J; Ning MS; Feng H; Li H; Bahig H; Brooks ED; Welsh JW; Ye R; Miao H; Chang JY
    Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):90-99. PubMed ID: 31586665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and external validation of a nomogram to predict overall survival following stereotactic body radiotherapy for early-stage lung cancer.
    Baker S; Bakunina K; Duijm M; Hoogeman MS; Cornelissen R; Antonisse I; Praag J; Heemsbergen WD; Nuyttens JJ
    Radiat Oncol; 2020 Apr; 15(1):89. PubMed ID: 32321553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
    Zhang X; Shi X; Zhao H; Jia X; Yang Y
    Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of EGFR mutation status in patients with stage III non-squamous non-small cell lung cancer treated with chemoradiotherapy].
    Li F; Bai H; Li X; Wu M; Yu R; Shi A; Yin L; Wang J; Zhu G
    Zhongguo Fei Ai Za Zhi; 2011 Sep; 14(9):715-8. PubMed ID: 21924037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiomics Nomogram for Predicting Locoregional Failure in Locally Advanced Non-small Cell Lung Cancer Treated with Definitive Chemoradiotherapy.
    Chen X; Tong X; Qiu Q; Sun F; Yin Y; Gong G; Xing L; Sun X
    Acad Radiol; 2022 Feb; 29 Suppl 2():S53-S61. PubMed ID: 33308945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of nomograms for predicting survival of elderly patients with stage I small-cell lung cancer.
    Yang Y; Sun S; Wang Y; Xiong F; Xiao Y; Huang J
    Bosn J Basic Med Sci; 2021 Oct; 21(5):632-641. PubMed ID: 33577444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non-small-cell Lung Cancer.
    Nakamura M; Kageyama SI; Niho S; Okumura M; Hojo H; Motegi A; Nakamura N; Zenda S; Yoh K; Goto K; Akimoto T
    Clin Lung Cancer; 2019 May; 20(3):e256-e264. PubMed ID: 30926356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting severe acute radiation pneumonitis in patients with non-small cell lung cancer receiving postoperative radiotherapy: Development and internal validation of a nomogram based on the clinical and dose-volume histogram parameters.
    Tang X; Li Y; Tian X; Zhou X; Wang Y; Huang M; Ren L; Zhou L; Xue J; Ding Z; Zhu J; Xu Y; Peng F; Wang J; Lu Y; Gong Y
    Radiother Oncol; 2019 Mar; 132():197-203. PubMed ID: 30385172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive model of the first failure pattern in patients receiving definitive chemoradiotherapy for inoperable locally advanced non-small cell lung cancer (LA-NSCLC).
    Zhu X; Hou R; Li X; Jiang C; Xia W; Fu X
    Radiat Oncol; 2020 Feb; 15(1):43. PubMed ID: 32070383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markers.
    Xie D; Allen MS; Marks R; Jiang G; Sun Z; Nichols F; Zhang M; Chen C; Aubry MC; Jatoi A; Garces YI; Mansfield A; Wigle D; Molina J; Deschamps C; Yang P
    Eur J Cardiothorac Surg; 2018 Jun; 53(6):1214-1222. PubMed ID: 29293957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and Validation of Nomogram Model Integrated With Inflammation-Based Factors for the Prognosis of Advanced Non-Small Cell Lung Cancer.
    Huang Z; Xing S; Zhu Y; Qu Y; Jiang L; Sheng J; Wang Q; Xu S; Xue N
    Technol Cancer Res Treat; 2020; 19():1533033820971605. PubMed ID: 33191854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of prognostic nomogram for T
    Mei W; Yao W; Song Z; Jiao W; Zhu L; Huang Q; An C; Shi J; Yu G; Sun P; Zhang Y; Shen J; Xu C; Yang H; Wang Q; Zhu Z
    BMC Cancer; 2023 Jul; 23(1):715. PubMed ID: 37525124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nomogram integrating gene expression signatures with clinicopathological features to predict survival in operable NSCLC: a pooled analysis of 2164 patients.
    Wu J; Zhou L; Huang L; Gu J; Li S; Liu B; Feng J; Zhou Y
    J Exp Clin Cancer Res; 2017 Jan; 36(1):4. PubMed ID: 28057025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of surgery on survival in patients with stage III N2 small cell lung cancer: propensity score matching analysis and nomogram development and validation.
    Chai Y; Ma Y; Feng W; Lu H; Jin L
    World J Surg Oncol; 2021 Aug; 19(1):258. PubMed ID: 34461929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment and validation of a nomogram for predicting the benefit of concurrent chemotherapy in stage II nasopharyngeal carcinoma: A study based on a phase III randomized clinical trial with 10-year follow-up.
    Sun XS; Li XY; Xiao BB; Liu SL; Chen QY; Tang LQ; Mai HQ
    Oral Oncol; 2020 Jan; 100():104490. PubMed ID: 31790913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.